Payers

Five things for pharma marketers to know: Friday, April 28, 2017

Five things for pharma marketers to know: Friday, April 28, 2017

By

Express Scripts-Anthem deal highlights profitability for PBMs; Sarepta CEO steps down; study says NHS cancer drug fund was ineffective

J&J blames lower Xarelto and Invokana sales on payer pressure

J&J blames lower Xarelto and Invokana sales on payer pressure

By

The drugmaker said it has been forced to provide higher rebates to PBMs and insurers for certain drugs.

Genentech urges broader adoption of value-based payment models

Genentech urges broader adoption of value-based payment models

By

A study published in Health Affairs detailed an outcomes-based pilot developed by the drugmaker and Priority Health, a Michigan-based health insurer.

Five things for pharma marketers to know: Thursday, February 23, 2017

Five things for pharma marketers to know: Thursday, February 23, 2017

By

Harvard Pilgrim signs pay-for-performance deals with Lilly and Amgen; new advocacy group wants lower drug prices; Zykadia gets priority review

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

By

Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.

Pharma/Payer Collaboration: A Kumbaya Moment or a Passing Trend?

Pharma/Payer Collaboration: A Kumbaya Moment or a Passing Trend?

By

The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.

Merck and Aetna pair population health with risk-sharing, in two deals

Merck and Aetna pair population health with risk-sharing, in two deals

By

But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?

Infographic: What payers want from pharma

Infographic: What payers want from pharma

One pharmacy director would like to see a lot more comparative data about new therapies.

Five things for pharma marketers to know: Thursday, January 19, 2017

Five things for pharma marketers to know: Thursday, January 19, 2017

By

The FDA releases three documents; PBM rebates eating into drugmaker revenue: PhRMA; most oncologists on Twitter receive money from pharma

Pharma pushes to share off-label info with payers at FDA hearing

Pharma pushes to share off-label info with payers at FDA hearing

By

Insurers and pharmacy benefit managers already have a sophisticated understanding of clinical data, the industry argued.

The drug industry wins pricing battle in California, likely to fare better with Trump

The drug industry wins pricing battle in California, likely to fare better with Trump

By

But experts say that drug pricing will remain a significant issue for the industry going forward into a non-election year.

Best Multichannel Campaign (Large Product Size) of 2016

Best Multichannel Campaign (Large Product Size) of 2016

By

The Ways In campaign was UnitedHealthcare's first consumer advertising effort.

The Titanium Award: Best in Show in 2016

The Titanium Award: Best in Show in 2016

By

The multichannel effort — UnitedHealthcare's inaugural consumer brand advertising campaign — launched in March 2015 with the TV commercial Our Song.

Why Any Merger is the Last Resort of Lousy Marketers

Why Any Merger is the Last Resort of Lousy Marketers

By

Really? Is this the new healthcare math — the fewer the insurance companies, the greater the competition and the lower the premiums?

Five things for pharma marketers to know: Friday, September 9, 2016

Five things for pharma marketers to know: Friday, September 9, 2016

By

New Cigna campaign features TV doctors; Walgreens to divest 1,000 stores; senators question Aetna's health exchange exit

MM&M's top 5 stories in August 2016

MM&M's top 5 stories in August 2016

By

Shire hires Jennifer Aniston for a disease awareness campaign; critics argue that the direct-to-consumer ads for Opdivo are misleading, while Merck's Keytruda takes the lead in first-line cancer

Health exchanges, Obama administration challenged by recent insurer exits

Health exchanges, Obama administration challenged by recent insurer exits

By

The pull-back of insurance providers has left state-run health exchanges and the Obama administration facing a difficult communications challenge.

Five things for pharma marketers to know: Monday, August 29, 2016

Five things for pharma marketers to know: Monday, August 29, 2016

By

Mylan to launch generic EpiPen; the majority of NCCN guideline writers report conflicts of interest; Sanofi reports new trial data for Praluent

The co-pay card debate simmers, as payers push back

The co-pay card debate simmers, as payers push back

By

Will this payer pressure pose an existential threat to co-pay cards even though patients love them?

Lobbyists create off-label principles following FDA lawsuits

By

PhRMA and BIO, which represent life sciences firms, developed principles about sharing truthful and non-misleading information with payers and providers.

Five things for pharma marketers to know: Monday, August 15, 2016

Five things for pharma marketers to know: Monday, August 15, 2016

By

Express Scripts does not disclose names of formulary board members; Endo withdrew abuse-deterrent formulation for opioid; BI to collect real-world data on Praxbind

Analysts: Payers moving to address MS market as prices rise

Analysts: Payers moving to address MS market as prices rise

By

The impending payer crackdown of the cost of MS drugs could portend the fate of other specialty drug markets, according to analysts.

Five things for pharma marketers to know: Tuesday, August 9, 2016

Five things for pharma marketers to know: Tuesday, August 9, 2016

By

Novo Nordisk attributes slow growth to biosimilars, pricing; Dentsu acquires majority stake in Merkle; AZ lung cancer drug fails late-stage trial

PBMs push forward toward outcomes-based pricing, despite challenges

PBMs push forward toward outcomes-based pricing, despite challenges

By

The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.

PBMs unveil 2017 formularies, retain focus on exclusions

PBMs unveil 2017 formularies, retain focus on exclusions

By

Express Scripts and CVS Health revealed their formularies with Pfizer's Xeljanz making the jump from excluded to preferred for Express Scripts.

Five things for pharma marketers to know: Tuesday, July 5, 2016

Five things for pharma marketers to know: Tuesday, July 5, 2016

By

States and insurers are lifting restrictions on HCV drugs; Teva's request to join PhRMA raises eyebrows; Merck partners with GPO

Five things for pharma marketers to know: Wednesday, May 11, 2016

Five things for pharma marketers to know: Wednesday, May 11, 2016

By

Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies

Intouch Solutions' Weissberg on the rising payer voice

Intouch Solutions' Weissberg on the rising payer voice

By

The group director of Intouch Solutions' newly launched market access business is betting that the payer will gain in influence.

Amgen takes issue with yet-to-be published multiple-myeloma drug report

Amgen takes issue with yet-to-be published multiple-myeloma drug report

By

The drugmaker instead suggested using an economic model it developed.

Five things for pharma marketers to know: Friday, March 4, 2016

Five things for pharma marketers to know: Friday, March 4, 2016

By

New PhRMA CEO issues policy strategy; study assess patient response to immuno-oncology drugs; Twitter may be an effective way to talk about clinical trials

Opinion

How to Shatter the Glass Ceiling

How Pharma Can Benefit from the Transformation of Pharmacy

Who Needs a Gold Watch, Anyway?

Newsletters

Live at MM&M Transforming Healthcare

Pharma faces its 'oh, shit' moment

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Merck, Takeda execs: Is AI the new bad app?

One executive referred to AI as a "black box" and as the "Tower of Babel."

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

Admetsys wins the 2017 MM&M Startup Showdown

The artificial pancreas can provide value to the health system.

Top 40 Healthcare Transformers

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts

For the first time MM&M honors a group of 10 agency execs.